Nonsteroidal MRAs: Latest Evidence of Cardiorenal Protection in CKD and T2D - a podcast by ReachMD

CME credits: 0.25

Valid until: 28-02-2023

Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mras-latest-evidence-of-cardiorenal-protection-in-ckd-and-t2d/13298/

Achieving optimal outcomes when treating patients with chronic kidney disease (CKD) in type 2 diabetes (T2D) remains a challenge due to the multidisciplinary response needed to prevent progressive renal dysfunction. Low screening rates and underdiagnosis impede early interventions. On the other hand, early diagnosis and regular screening of CKD in T2D set the stage for clinicians to optimize drug therapy to prevent progression to end-stage renal disease while aggressively managing comorbid T2D and other CKD risk factors.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD